The clinical utility of circulating tumor DNA in colorectal cancer: A narrative review DOI Creative Commons
Vijaya Lakshmi,

Meenakshi Rakesh,

M P Narmadha

et al.

Cancer Research Statistics and Treatment, Journal Year: 2024, Volume and Issue: 7(4), P. 435 - 446

Published: Oct. 1, 2024

ABSTRACT Circulating free DNA (cfDNA) refers to extracellular fragments (50-200 base pairs) in the blood, released during cell apoptosis or necrosis, and linked tissue injury. Microbial cfDNA (cfmDNA), derived from bacteria, can also be present both healthy individuals patients with colorectal cancer, some species specific these categories. tumor (ctDNA), a subset of cfDNA, originates tumors reflects their genetic profile. Elevated ctDNA levels result increased death impaired clearance progression. Healthy typically have 30 ng/mL whereas cancer show up 1000 ng/mL. Patients colon often exhibit higher concentrations (500 ng/mL) compared rectal (250 ng/mL). is valuable noninvasive biomarker for monitoring progression prognosis, particularly since disease diagnosed at advanced stages. Its widespread dispersion circulating aids tracking recurrence. This article reviews life cycle, analysis methods, screening approaches, clinical applications, limitations, future perspectives ctDNA. The data this review were extracted PubMed, ScienceDirect, ResearchGate, Scopus, UpToDate, covering publications January 2016 December 2023. Out 95 retrieved articles, 3 removed before screening. Two duplicates, 1 was ineligible record. After reviewing 92 articles eligibility, 7 excluded: being non-human studies, 2 not exclusive lacking utility. We selected 85 final analysis. For purpose discussion, we referred various papers on as well ( n = 15).

Language: Английский

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine DOI Creative Commons
Ying Bao,

Dejing Zhang,

Huihui� Guo

et al.

Cancer Science, Journal Year: 2024, Volume and Issue: 115(4), P. 1060 - 1072

Published: Feb. 3, 2024

Abstract Liquid biopsy is emerging as a pivotal tool in precision oncology, offering noninvasive and comprehensive approach to cancer diagnostics management. By harnessing biofluids such blood, urine, saliva, cerebrospinal fluid, pleural effusions, this technique profiles key biomarkers including circulating tumor DNA, cells, microRNAs, extracellular vesicles. This review discusses the extended scope of liquid biopsy, highlighting its indispensable role enhancing patient outcomes through early detection, continuous monitoring, tailored therapy. While advantages are notable, we also address challenges, emphasizing necessity for precision, cost‐effectiveness, standardized methodologies broader application. The future trajectory set expand reach personalized medicine, fueled by technological advancements collaborative research.

Language: Английский

Citations

20
Applications of dielectrophoresis in microfluidic-based exosome separation and detection DOI
Mei Lan, Fang Yang

Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 491, P. 152067 - 152067

Published: May 9, 2024

Language: Английский

Citations

9
Liquid Biopsy in Cancer Management: Integrating Diagnostics and Clinical Applications DOI Creative Commons

Shashwat Pandey,

Preeti Kumari Yadav

Practical Laboratory Medicine, Journal Year: 2024, Volume and Issue: unknown, P. e00446 - e00446

Published: Dec. 1, 2024

Liquid biopsy is an innovative, minimally invasive diagnostic tool revolutionizing cancer management by enabling the detection and analysis of cancer-related biomarkers from bodily fluids such as blood, urine, or cerebrospinal fluid. Unlike traditional tissue biopsies, which require procedures, liquid offers a more accessible repeatable method for tracking progression, detecting early-stage cancers, monitoring therapeutic responses. The technology primarily focuses on analyzing circulating tumor cells (CTCs), DNA (ctDNA), other cancer-derived genetic materials. These provide critical information heterogeneity, mutation profiles, potential drug resistance. In clinical practice, has demonstrated its utility in identifying actionable mutations, guiding personalized treatment strategies, assessing minimal residual disease (MRD). While holds immense promise, challenges related to sensitivity, specificity, standardization remain. Efforts optimize pre-analytical analytical processes, along with establishment robust regulatory frameworks, are crucial widespread adoption. This abstract highlights transformative diagnosis, prognosis, monitoring, emphasizing role advancing oncology. Further research, trials, harmonization will be vital realizing full precision care.

Language: Английский

Citations

4
Polymerase Chain Reaction Chips for Biomarker Discovery and Validation in Drug Development DOI Creative Commons
Dang-Khoa Vo, Kieu The Loan Trinh

Micromachines, Journal Year: 2025, Volume and Issue: 16(3), P. 243 - 243

Published: Feb. 20, 2025

Polymerase chain reaction (PCR) chips are advanced, microfluidic platforms that have revolutionized biomarker discovery and validation because of their high sensitivity, specificity, throughput levels. These miniaturize traditional PCR processes for the speed precision nucleic acid detection relevant to advancing drug development. Biomarkers, which useful in helping explain disease mechanisms, patient stratification, therapeutic monitoring, hard identify validate due complexity biological systems limitations techniques. The challenges respond include high-throughput capabilities coupled with real-time quantitative analysis, enabling researchers novel biomarkers greater accuracy reproducibility. More recent design improvements further expanded functionality also digital multiplex technologies. Digital ideal quantifying rare biomarkers, is essential oncology infectious research. In contrast, enable simultaneous analysis multiple targets, therefore simplifying validation. Furthermore, single-cell made it possible detect at unprecedented resolution, hence revealing heterogeneity within cell populations. transforming development, target identification, efficacy assessment. They play a major role development companion diagnostics and, therefore, pave way personalized medicine, ensuring right receives treatment. While this tremendously promising technology has exhibited many regarding its scalability, integration other omics technologies, conformity regulatory requirements, still prevail. Future breakthroughs chip manufacturing, artificial intelligence, multi-omics applications will expand capabilities. not only be important acceleration but raising bar improving outcomes hence, global health care as these technologies continue mature.

Language: Английский

Citations

0
Exosomes in Precision Oncology and Beyond: From Bench to Bedside in Diagnostics and Therapeutics DOI Open Access

Emile M. Youssef,

Dannelle Palmer,

Brandon Fletcher

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 940 - 940

Published: March 10, 2025

Exosomes have emerged as pivotal players in precision oncology, offering innovative solutions to longstanding challenges such metastasis, therapeutic resistance, and immune evasion. These nanoscale extracellular vesicles facilitate intercellular communication by transferring bioactive molecules that mirror the biological state of their parent cells, positioning them transformative tools for cancer diagnostics therapeutics. Recent advancements exosome engineering, artificial intelligence (AI)-driven analytics, isolation technologies are breaking barriers scalability, reproducibility, clinical application. Bioengineered exosomes being leveraged CRISPR-Cas9 delivery, while AI models enhancing biomarker discovery liquid biopsy accuracy. Despite these advancements, key obstacles heterogeneity populations lack standardized protocols persist. This review synthesizes pioneering research on biology, molecular translation, emphasizing dual roles both mediators tumor progression intervention. It also explores emerging areas, including microbiome–exosome interactions integration machine learning exosome-based medicine. By bridging innovation with translational strategies, this work charts a forward-looking path integrating into next-generation care, setting it apart comprehensive guide overcoming technological hurdles rapidly evolving field.

Language: Английский

Citations

0
Predictive biomarkers: guiding personalized cancer therapies DOI
Himanshu Sharma, Rashmi Pathak, Praveen Halagali

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 239 - 262

Published: Jan. 1, 2025

Language: Английский

Citations

0
The role of exosomes in bladder cancer immunotherapy DOI Creative Commons
Mohammad Mousaei Ghasroldasht, Piyush K. Agarwal

Journal of the National Cancer Center, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

Citations

0
New paradigms to break barriers in early cancer detection for improved prognosis and treatment outcomes DOI
Irfan Ahmad, Saade Abdalkareem Jasim, Madan Kumar Sharma

et al.

The Journal of Gene Medicine, Journal Year: 2024, Volume and Issue: 26(8)

Published: Aug. 1, 2024

The uncontrolled growth and spread of cancerous cells beyond their usual boundaries into surrounding tissues characterizes cancer. In developed countries, cancer is the leading cause death, while in underdeveloped nations, it ranks second. Using existing diagnostic tools has increased early detection rates, which crucial for effective treatment. recent decades, there been significant progress cancer-specific survival rates owing to advances ability accurately identify precursor lesions a aspect screening programs, as enables treatment initiation, lower long-term incidence invasive improved overall prognosis. However, these methods have limitations, such high costs technical challenges, can make accurate diagnosis certain deep-seated tumors difficult. To achieve prognosis, essential continue developing cutting-edge technologies molecular biology imaging.

Language: Английский

Citations

2
Advances in biomarker identification and validation for oral cancer diagnosis and prognosis DOI Creative Commons

A. S. Vickram,

S. Manikandan

Oral Oncology Reports, Journal Year: 2024, Volume and Issue: 10, P. 100346 - 100346

Published: April 16, 2024

• Cutting-edge biomarker discovery, can apply genomics, proteomics and metabolomics technologies to discover novel biomarkers for the early detection accurate prognosis of oral cancer. Rigorous validation processes, identified brought by genomic should be deeply investigated using rigorous methods before they considered as good quality materials. Clinical application exposure cancer treatment field, incorporating into clinical practice will radically change detection, planning prognostic assessment increase survival rates or decrease overall disease burden.

Language: Английский

Citations

0
Diagnostic Challenges and Treatment Options for Mucocle of the Appendix: A Comprehensive Review DOI Open Access

Vasundara Gopalan,

Imran Ali Khan,

Anup A Zade

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 4, 2024

Mucocles of the appendix, encompassing mucinous cystadenomas and cystadenocarcinomas, represent rare but clinically significant appendiceal lesions characterized by accumulation mucin within appendix lumen. This review explores diagnostic complexities treatment strategies associated with mucocles, emphasizing importance its accurate recognition management. Diagnostic challenges arise due to overlapping symptoms acute appendicitis other pathologies, necessitating a multidimensional approach that includes imaging, histopathological analysis, clinical correlation. Treatment options range from appendectomy for benign more extensive surgical procedures, such as right hemicolectomy malignant forms. Prognostic factors, including histological subtype tumor size, influence decisions long-term outcomes. By synthesizing current evidence insights, this aims provide comprehensive framework clinicians navigate mucocles offering perspectives can guide effective management future research endeavors.

Language: Английский

Citations

0